IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma
´ëÇѺ´¸®ÇÐȸÁö 2014³â 48±Ç 2È£ p.108 ~ p.116
¹ÚÁö¿µ(Park Ji-Young) - Keimyung University College of Medicine Department of Pathology
Ãֹ̼±(Choe Mi-Sun) - Keimyung University College of Medicine Department of Pathology
(Kang Yun-A) - Keimyung University College of Medicine Department of Pathology
ÀÌ»ó¼÷(Lee Sang-Sook) - Keimyung University College of Medicine Department of Pathology
Abstract
Background: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been reported as a prognostic biomarker in various cancers. To validate IMP3 as a prognostic biomarker in renal cell carcinoma (RCC), we investigated the expression of IMP3, p53, and Ki-67, and their associations with clinicopathologic outcomes.
Methods: We studied 148 clear cell RCCs (CCRCCs) from patients who underwent radical nephrectomy. The expression levels of IMP3, p53, and Ki-67 were assessed by immunohistochemical staining and the clinical and pathologic parameters were retrospectively reviewed.
Results: Twenty-nine percent of CCRCCs expressed IMP3. Forty-one percent of IMP3-immunopositive tumors developed metastases, while only 11.4% of IMP3-negative tumors developed metastases (p<.001). A Kaplan-Meier curve showed that patients with IMP3- immunopositive tumors had lower metastasis-free survival and cancer-specific survival than did those with IMP3-immunonegative tumors (p<.001 and p<.001, respectively). Expression of high Ki-67 proliferation index was also associated with a higher metastatic rate. In the multivariate Cox regression analysis, pT stage and IMP3-positivity were independently associated with diseasespecific survival.
Conclusions: IMP3 is an independent prognostic biomarker for patients with CCRCC to predict metastasis and poor outcome.
Å°¿öµå
Carcinoma, renal cell, IMP3, Tumor suppressor protein p53, Ki-67, Neoplasm metastasis
KMID :
0357920140480020108
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)